# NCT04140487 (NCT04140487)

> Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm

No report yet. It can be ordered.

- Drugs tested: gilteritinib plus azacitidine plus venetoclax
- Indication: newly diagnosed or relapsed/refractory FLT3-mutated acute myeloid leukemia

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04140487
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: M.D. Anderson Cancer Center
- Conditions: Recurrent Acute Myeloid Leukemia; Recurrent Chronic Myelomonocytic Leukemia; Recurrent Myelodysplastic/Myeloproliferative Neoplasm; Refractory Acute Myeloid Leukemia; Refractory Chronic Myelomonocytic Leukemia; Refractory Myelodysplastic/Myeloproliferative Neoplasm
- Interventions: Azacitidine; Gilteritinib; Venetoclax
- Enrollment: 97
- Primary outcome: Maximum-tolerated dose (MTD) of gilteritinib (Phase I)
- Primary outcome: Overall response rate (OR) (Phase II)

## Indexed commentary on NCT04140487 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct04140487